The EUREGHA – European Regional and Local Health Authorities Secretariat was pleased to take part in the kick-off meeting of the PREDI-LYNCH project, held in Heidelberg, Germany.
PREDI-LYNCH is a six-year Horizon Europe initiative coordinated by Oslo University Hospital and brings together 28 partners from 16 countries. The project aims to develop validated, non-invasive liquid biopsy tests for the early detection and personalised prevention of cancers linked to Lynch Syndrome – a hereditary condition that significantly increases the risk of colorectal, endometrial, and other cancers.
EUREGHA will play an active role in the consortium by supporting stakeholder engagement and dissemination activities, with a particular focus on involving regional and local health authorities. We will also contribute to the development of policy recommendations to help ensure that PREDI-LYNCH’s outcomes can be integrated into cancer strategies across Europe.
This work reflects EUREGHA’s broader mission of connecting regions and local health actors to European innovation, ensuring that research results translate into real benefits for patients and health systems.
Predi-Lynch is the second project with EUREGHA involvement under the Cancer Mission, joining the ongoing project ONCODIR – Evidence-based Participatory Decision Making for Cancer Prevention through implementation.
Stay informed about the project’s progress by following the PREDI-LYNCH LinkedIn profile and visiting the official project website.
